2024

• Campbell, A., Trotman, J., Lane, S., Dickinson, M., Quach, H., Enjeti, A., Ku, M., Gregory, G., Hapgood, G., Ho, P., Greenwood, M., Mulligan, S., et al (2024). Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies. Internal Medicine Journal, 54(2), 328-336. [More Information]
• Hungria, V., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Martinez, G., Balarí, A., Sandhu, I., Cerchione, C., Ganly, P., Ho, P., et al (2024). Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 391(5), 393-407. [More Information]
• Lin, Y., Hajek, R., Ho, P., Kastritis, E., Martinez-Lopez, J., Mateos, M., Mikhael, J., Moreau, P., Nagarajan, C., Nooka, A., et al (2024). Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. The Lancet Oncology. [More Information]
• Ho, P., Joshua, D., Spencer, A., Mollee, P., Bryant, C., Enjeti, A., Horvath, N., Butcher, B., Trotman, J., Gibbs, S. (2024). Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse. Clinical Lymphoma, Myeloma and Leukemia. [More Information]
• Favaloro, J., Joshua, D., Ho, P., Bryant, C., Abadir, E., Gardiner, S., Yang, S., King, T., Nassif, N., Sedger, L., et al (2024). Single-cell analysis of the CD8+ T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69- subset suggesting potent cytotoxic effectors exist within the tumor bed. Haematologica, 109(4), 1220-1232. [More Information]

2023

• Li, E., Walsh, R., Ho, P. (2023). Benign clinical phenotype of co-inherited congenital dyserythropoietic anaemia type I and heterozygous haemoglobin Lepore. European Journal of Haematology. [More Information]
• Burge, C., Vanguru, V., Ho, P. (2023). Chimeric antigen receptor T-cell therapy. Australian Prescriber, 46(2), 36-39. [More Information]
• San-Miguel, J., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S., Roeloffzen, W., Van De Donk, N., Dytfeld, D., Ho, P., et al (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine, 389(4), 335-347. [More Information]
• Dimopoulos, M., van de Donk, N., Weisel, K., Badros, A., Beksac, M., Hillengass, J., Mohty, M., Ho, P., Ntanasis-Stathopoulos, I., Mateos, M., et al (2023). Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. The Lancet Oncology, 24(7), e293-e311. [More Information]
• Anderson, S., Perram, J., Nelson, A., Matthews, S., Gou, M., Ho, P. (2023). Pregnancy and assisted reproductive technology use in Australian female transfusion-dependent haemoglobinopathy patients: a 20-year retrospective analysis. Internal Medicine Journal. [More Information]
• Nelson, A., Kidson-Gerber, G., Kaplan, Z., Carter, T., Cole-Sinclair, M., Barbaro, P., Wood, E., Ho, P., Haysom, H., Waters, N., et al (2023). Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry. Internal Medicine Journal. [More Information]
• Sim, S., Kalff, A., Tuch, G., Mollee, P., Ho, P., Harrison, S., Gibbs, S., Prince, H., Spencer, A., Joshua, D., et al (2023). The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 53(5), 819-824. [More Information]

2022

• Tam, C., Ho, P., Purtill, D., Blyth, E., Butler, J., Dickinson, M., Harrison, S. (2022). Fitness criteria for Australian patients referred for chimeric antigen receptor T‐cell therapy. Internal Medicine Journal, 52(8), 1454-1456. [More Information]
• Jaeger, U., Tam, C., Borchmann, P., McGuirk, J., Johansen, M., Waller, E., Jaglowski, S., Andreadis, C., Foley, S., Ho, P., et al (2022). Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 6(16), 4816-4820. [More Information]
• Richardson, P., Mateos, M., Vangsted, A., Ramasamy, K., Abildgaard, N., Ho, P., Quach, H., Bahlis, N. (2022). The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Review of Proteomics. [More Information]
• Fowler, N., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J., Bachy, E., Ho, P., et al (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nature Medicine, 28(2), 325-332. [More Information]
• Talaulikar, D., Joshua, D., Ho, P., Gibson, J., Quach, H., Gibbs, S., Ling, S., Ward, C., Augustson, B., Trotman, J., et al (2022). Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. [More Information]

2021

• Ramesh, M., Favaloro, J., Bryant, C., Ho, P., Abadir, E. (2021). Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets. Leukemia & Lymphoma, 62(8), 2005-2009. [More Information]
• McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A., Mulligan, S., Trotman, J., Ho, P., Greenwood, M., et al (2021). COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 51(5), 763-768. [More Information]
• Bergin, K., Wellard, C., Augustson, B., Cooke, R., Blacklock, H., Harrison, S., Ho, P., King, T., Quach, H., Mollee, P., et al (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 56(10), 2533-2543. [More Information]
• Bergin, K., Wellard, C., Moore, E., McQuilten, Z., Blacklock, H., Harrison, S., Ho, P., King, T., Quach, H., Mollee, P., et al (2021). The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 21(6), e510-e520. [More Information]
• Joshua, D., Vuckovic, S., Favaloro, J., Lau, K., Yang, S., Bryant, C., Gibson, J., Ho, P. (2021). Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. Frontiers in Immunology, 12, 620596. [More Information]

2020

• Domenica Cappellini, M., Viprakasit, V., Taher, A., Georgiev, P., Kuo, K., Coates, T., Voskaridou, E., Liew, H., Pazgal-Kobrowski, I., Forni, G., Ho, P., et al (2020). A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. New England Journal of Medicine, 382(13), 1219-1231. [More Information]
• Di Ciaccio, P., McCaughan, G., Trotman, J., Ho, P., Cheah, C., Gangatharan, S., Wight, J., Ku, M., Quach, H., Gasiorowski, R., Mulligan, S., Hamad, N., et al (2020). Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal, 50(6), 667-679. [More Information]
• Bahlis, N., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Ho, P., Kim, K., Takezako, N., Moreau, P., et al (2020). Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 34(7), 1875-1884. [More Information]
• Facon, T., Niesvizky, R., Mateos, M., Siegel, D., Rosenbaum, C., Bringhen, S., Weisel, K., Ho, P., Ludwig, H., Kumar, S., et al (2020). Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances, 4(21), 5449-5459. [More Information]
• Vuckovic, S., Bryant, C., Lau, K., Yang, S., Favaloro, J., McGuire, H., Clark, G., Fazekas de St Groth, B., Marsh-Wakefield, F., Nassif, N., McCulloch, D., Brown, C., Larsen, S., Gibson, J., Joshua, D., Ho, P., et al (2020). Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients. Blood Advances, 4(19), 4593-4604. [More Information]
• Abadir, E., Silveira, P., Gasiorowski, R., Ramesh, M., Romano, A., Mekkawy, A., Lo, T., Kabani, K., Sutherland, S., Pietersz, G., Ho, P., Larsen, S., Clark, G., et al (2020). Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Advances, 4(7), 1206-1216. [More Information]

2019

• Joshua, D., Bryant, C., Dix, C., Gibson, J., Ho, J. (2019). Biology and therapy of multiple myeloma. Medical Journal of Australia, 210(8), 375-380. [More Information]
• Ho, P., Hiwase, D., Ramakrishna, R., Viiala, N., Solterbeck, A., Traficante, R., Zor, E., Gervasio, O., High, L., Ross, D., et al (2019). Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. HemaSphere, 3(3), 1-11. [More Information]
• Abadir, E., Gasiorowski, R., Lai, K., Kupresanin, F., Romano, A., Silveira, P., Lo, T., Fromm, P., Kennerson, M., Iland, H., Ho, P., Hart, D., Clark, G., et al (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology, 13(10), 2107-2120. [More Information]
• Anderson, S., Kiernan, M., Ho, P. (2019). Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 19(4), e169-e171. [More Information]
• Marsh-Wakefield, F., Kruzins, A., McGuire, H., Yang, S., Bryant, C., Fazekas de St Groth, B., Nassif, N., Byrne, S., Gibson, J., Brown, C., Larsen, S., McCulloch, D., Joshua, D., Ho, P., et al (2019). Mass Cytometry Discovers Two Discrete Subsets of CD39-Treg Which Discriminate MGUS From Multiple Myeloma. Frontiers in Immunology, 10, 1-12. [More Information]
• Yeung, J., van Hal, S., Ho, P. (2019). Prolonged Immunosuppression in Relapsed, Refractory Multiple Myeloma Leading to Cerebral Toxoplasmosis and Progressive Multifocal Leukoencephalopathy. Clinical Lymphoma, Myeloma and Leukemia, 19(12), e625-e628. [More Information]
• Ho, P., Moore, E., McQuilten, Z., Wellard, C., Bergin, K., Augustson, B., Blacklock, H., Harrison, S., Horvath, N., King, T., et al (2019). Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma, Myeloma and Leukemia, 19(8), e415-e424. [More Information]
• Schuster, S., Bishop, M., Tam, C., Waller, E., Borchmann, P., McGuirk, J., Jager, U., Jaglowski, S., Andreadis, C., Westin, J., Ho, P., et al (2019). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 380(1), 45-56. [More Information]

2018

• Hsu, J., Bryant, C., Papadimitrious, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology, 7(4), e1419114-1-e1419114-11. [More Information]
• Dimopoulos, M., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P., Kim, K., et al (2018). Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica, 103(12), 2088-2096. [More Information]
• Thompson, A., Walters, M., Kwiatkowski, J., Rasko, J., Ribeil, J., Hongeng, S., Magrin, E., Schiller, G., Payen, E., Semeraro, M., Ho, P., et al (2018). Gene Therapy in Patients with Transfusion-Dependent [Beta]-Thalassemia. New England Journal of Medicine, 378(16), 1479-1493. [More Information]
• Xu, X., Dimopoulos, M., Sonneveld, P., Ho, P., Belch, A., Leiba, M., Capra, M., Gomez, D., Medvedova, E., Iida, S., et al (2018). Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Advances in Therapy, 35(11), 1859-1872. [More Information]
• Scott, A., Weber, N., Tiley, C., Taylor, K., Taper, J., Harrison, S., Chan, K., Stark, R., Lee, C., Morris, K., Ho, P., et al (2018). Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia & Lymphoma, 59(6), 1514-1516. [More Information]

2017

• Ho, P., Bajel, A., Burbury, K., Dunlop, L., Durrant, S., Forsyth, C., Perkins, A., Ross, D. (2017). A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Internal Medicine Journal, 47(3), 262-268. [More Information]
• Lee, O., Horvath, N., Lee, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Gibson, J., Ward, C., et al (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 47(8), 938-951. [More Information]
• Ho, P., Tay, L., Teo, J., Marlton, P., Grigg, A., St Pierre, T., Brown, G., Badcock, C., Traficante, R., Gervasio, O., et al (2017). Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). European Journal of Haematology, 98(2), 97-105. [More Information]
• Quach, H., White, D., Spencer, A., Ho, P., Bhutani, D., White, M., Inamdar, S., Morris, C., Ou, Y., Gyger, M. (2017). Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemotherapy and Pharmacology, 79(6), 1067-1076. [More Information]
• Ho, P., Jelfs, P., Nguyen, P., Sintchenko, V., Fox, G., Marks, G. (2017). Pooling sputum samples to improve the feasibility of Xpert(®) MTB/RIF in systematic screening for tuberculosis. International Journal of Tuberculosis and Lung Disease, 21(5), 503-508. [More Information]
• Talaulikar, D., Tam, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Gibson, J., Trotman, J., Ward, C., et al (2017). Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47(1), 35-49. [More Information]

2016

• Bryant, C., Fromm, P., Kupresanin, F., Clark, G., Lee, K., Clarke, C., Silveira, P., Suen, H., Brown, R., Newman, E., Ho, P., Bradstock, K., Joshua, D., Hart, D., et al (2016). A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. Immunology and Cell Biology, 94(5), 447-457. [More Information]
• Bergin, K., Moore, E., McQuilten, Z., Wood, E., Augustson, B., Blacklock, H., Ho, P., Horvath, N., King, T., McNeil, J., et al (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology, 16(1), 1-8. [More Information]
• Crighton, G., Wood, E., Scarborough, R., Ho, P., Bowden, D. (2016). Haemoglobin disorders in Australia: where are we now and where will we be in the future? Internal Medicine Journal, 46(7), 770-779. [More Information]
• Suen, H., Brown, R., Yang, S., Weatherburn, C., Ho, P., Woodland, N., Nassif, N., Barbaro, P., Bryant, C., Hart, D., Gibson, J., Joshua, D. (2016). Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia, 30(8), 1716-1724. [More Information]
• Joshua, D., Suen, H., Brown, R., Bryant, C., Ho, P., Hart, D., Gibson, J. (2016). The T cell in myeloma. Clinical Lymphoma, Myeloma and Leukemia, 16(10), 537-542. [More Information]

2015

• Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., Harrison, S., Ho, P., Horvath, N., Jaksic, W., et al (2015). Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(4), 371-382. [More Information]
• Brown, R., Yang, S., Weatherburn, C., Gibson, J., Ho, P., Suen, H., Hart, D., Joshua, D. (2015). Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia, 29(2), 483-490. [More Information]
• Ho, P., Marlton, P., Tam, C., Stevenson, W., Ritchie, D., Bird, R., Dunlop, L., Durrant, S., Ross, D. (2015). Practical management of myelofibrosis with ruxolitinib. Internal Medicine Journal, 45(12), 1221-1230. [More Information]
• Suen, H., Brown, R., Yang, S., Ho, P., Gibson, J., Joshua, D. (2015). The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia, 29(7), 1621-1622. [More Information]
• Ho, P., Marks, G., Fox, G. (2015). The impact of sputum quality on tuberculosis diagnosis: a systematic review. International Journal of Tuberculosis and Lung Disease, 19(5), 537-544. [More Information]
• Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(1), 94-105. [More Information]
• Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talaulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(3), 335-343. [More Information]
• Brown, R., McAuliffe, S., Catalano, A., Ho, P., Nassif, N., Woodland, N., Hart, D., Weatherburn, C., Yang, S., Suen, H., Joshua, D., et al (2015). Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. Leukemia & Lymphoma, 56(9), 2714-2716. [More Information]

2014

• Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, P., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia & Lymphoma, 55(5), 1090-1098. [More Information]

2013

• Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]

2012

• Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 97(1), 64-72. [More Information]
• Ho, P., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia & Lymphoma, 53(9), 1728-1734. [More Information]

2011

• Ho, P., Tay, L., Lindeman, R., Catley, L., Bowden, D. (2011). Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Internal Medicine Journal, 41(7), 516-524. [More Information]
• Viprakasit, V., Ibrahim, H., Ha, S., Ho, P., Li, C., Chan, L., Chiu, C., Sutcharitchan, P., Habr, D., Domokos, G., et al (2011). Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology (online), 93(3), 319-328. [More Information]

2007

• Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. Molecular Cancer Therapeutics, 6(12), 3365s-3366s.
• Sanders, J., Crawford, B., Gibson, J., Ho, P., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
• Ling, S., Campbell, L., Ho, P., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), Clinical Malignant Haematology, (pp. 847-857). United States: McGraw Hill.
• Osborn, R., de Abreu Lourenço, R., Dalton, A., Houltram, J., Dowton, D., Joshua, D., Lindeman, R., Ho, P. (2007). Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in Health, 10(6), 451-456. [More Information]

2006

• Trent, R., Webster, B., Bowden, D., Gilbert, A., Ho, P., Lindeman, R., Lammi, A., Rowell, J., Hinchcliffe, M., Colley, A., et al (2006). Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing. Pathology, 38(6), 507-519. [More Information]
• Sze, D., Brown, R., Yang, S., Ho, P., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. Current Cancer Drug Targets, 6(4), 325-331. [More Information]
• Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, P. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]

2005

• Brown, R., Ho, P. (2005). Identification of Malignant Plasma Cells by mRNA In Situ Hybridization. Methods in molecular medicine, 113, 175-181.
• Joshua, D., Brown, R., Ho, P. (2005). Multiple myeloma: challenges and opportunities. Methods in molecular medicine, 113(Multiple Myeloma: Methods and Protocols), 1-4.
• Ho, P. (2005). Multiple Myeloma: Methods and Protocols. Totowa, NJ, USA: Humana Press.
• Gibson, J., Joshua, D., Ho, P., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), Oxford Handbook of Music Psychology. Oxford, UK: Oxford University Press.

2004

• Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. Leukemia and Lymphoma, 45(2), 363-371. [More Information]
• Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor βâ‚� In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748. [More Information]
• Gibson, J., Ho, P., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. Transplantation Proceedings, 36(8), 2501-2503. [More Information]
• Gibson, J., Ho, P., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. Transplantation Proceedings, 36(7), 1995-1998. [More Information]
• Joshua, D., Gibson, J., Brown, R., Ho, P. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), Multiple myeloma and related disorders, (pp. 29-46). UK: Hodder Arnold.
• Ho, P., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. American Journal of Cancer, 3(1), 47-66. [More Information]

2003

• Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, P., Raitakari, M., Basten, A., Joshua, D., Fazekas de St Groth, B. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia and Lymphoma, 44(10), 1667-1674. [More Information]
• Sze, D., Brown, R., Yang, S., Gibson, J., Ho, P., Fazekas de St Groth, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia and Lymphoma, 44(9), 1557-1568. [More Information]

2002

• Ho, P. (2002). Chromosomal and genetic abnormalities in myeloma. Clinical and Laboratory Haematology, 24(5), 259-269. [More Information]
• Ho, P., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology, 6(3), 276-300. [More Information]

2001

• Sze, D., Giesajtis,, G., Brown, R., Raitakari, M., Gibson, J., Ho, P., Baxter, A., Fazekas de St Groth, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. Blood, 98(9), 2817-2827.
• Ho, P., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood, 97, 490-495.

2000

• Ho, P., Thein, S. (2000). Gene regulation and deregulation: a beta globin perspective. Blood Reviews, 14, 78-93.